Case report of patient with a Cronkhite-Canada syndrome: sustained remission after treatment with corticosteroids and mesalazine

Sigrid Schulte 1*, Fabian Kütting 1, Jessica Mertens 1, Thomas Kaufmann 2, Uta Drebber 3, Dirk Nierhoff 1, Ulrich Töx 1 and Hans-Michael Steffen 1

Abstract

Background: Cronkhite-Canada syndrome is a rare disease of unknown etiology and the optimal treatment for this syndrome is unknown.

Case presentation: We present the case of a man who at the age of 66.0 years was diagnosed with Cronkhite-Canada syndrome (CCS). In addition to watery diarrhea, alopecia, and a complete loss of toenails and fingernails, the patient had been suffering from dysgeusia and rapid weight loss of more than 10.0 kg within a few months. The patient had recently incurred a distal radius fracture. During the initial endoscopy an extensive polyposis of the stomach and jejunum was found. The diagnosis of CCS was made and after initiation of a steroid therapy his diarrhea improved immediately. A discontinuation of the steroid therapy was not possible and mesalazine (1000 mg t.i.d.) was added to prednisolone (10.0 mg/d). This therapy led to a remission within 6.0 months with weight gain and normalization of serum albumin levels. The prednisolone dose was reduced to 7.5 mg/d. During the following year, the steroids could be further reduced and nails had regrown again. Within three years, all polyps had disappeared and the steroid therapy was finished while the dosage of mesalazine was reduced in a stepwise fashion. Four years later, the mesalazine was stopped and more than 14.0 years after the initial diagnosis the patient is still in complete remission without any treatment.

Conclusion: The optimal treatment for CCS is unknown. In our case, the initial combination therapy of corticosteroids plus mesalazine followed by a mesalazine monotherapy has led to a remarkable long-lasting remission with complete resolution of all intestinal polyps.

Keywords: Cronkhite-Canada syndrome, Mesalazine, Non-hereditary polyposis, Alopecia, Onychodystrophy

Introduction

Cronkhite-Canada syndrome is a rare non-hereditary disease of unknown etiology, first described in 1955 [1, 2]. Alongside a gastrointestinal hamartomatous polyposis and gastrointestinal symptoms such as diarrhea, other symptoms such as onychodystrophy, alopecia, hyperpigmentation of the skin, and rarely vitiligo [2] are associated with this condition. Its pathogenesis remains unclear; however, an autoimmune process is suspected due to increased IgG4 levels found in CCS polyps [3]. More than 500 cases have been described in the literature, 75.0% originate from Japan. The average age of onset is 59.0 years with a 3:2 male/female distribution [4].

Clinical course

Diarrhea represents the leading symptom in 80.0% of cases and as the initial symptom in 35.0% of all cases. Further symptoms include dysgeusia (41.0%), dry mouth (6.0%), and upper abdominal pain (9.0%). The disease tends to follow a progressive course with a high mortality.
as a result of cachexia, anemia, sepsis and shock [5, 6]. The 5-year-mortality rate is 55.0%, primarily due to gastrointestinal bleeding, infections, malnourishment, and severe electrolyte imbalance [4, 5, 7]. Besides fulminant and chronic disabling cases complete remissions have been described; however, these occur in only 5.0% of all cases [8]. Gastrointestinal polyposis due to CCS is principally non-neoplastic and rather inflammatory/hamartomatous in nature. Cases of malignant polyps following a typical adenoma-carcinoma sequence have been described [9–14] as well as colorectal carcinoma after malignant transformation of serrated polyps [15]. The elevated risk for colorectal carcinoma calls for aggressive screening in these patients. However, the detection of adenoma among the great number of hyperplastic inflammatory polyps is challenging [16]. Ward and Wolfsen recommend systematically resecting all polyps > 1.0 cm in order to prevent the development of colorectal carcinoma [8, 17].

**Differential diagnoses**

Ménétrier disease and other polyposis syndromes such as familial adenomatous polyposis, Gardner syndrome, juvenile polyposis, Peutz-Jeghers syndrome and Turcot syndrome have to be taken into consideration. Furthermore, protein-losing enteropathies such as chronic inflammatory bowel diseases, Whipple’s disease, or intestinal lymphangiectasia have to be ruled out [8, 18].

**Case presentation**

Upon first presentation to his local hospital, our patient was 66.0 years old and initially complained of diarrhea, alopecia and dystrophy of his nails (Fig. 1 A, C). He also had recently incurred a distal radius fracture. He described dysgeusia and had a reported weight loss of 10.0 kg in the past few months. He was a non-smoker and did not drink alcohol. His family history revealed no cases of gastrointestinal polyposis or colorectal malignancies.

The diagnosis of Cronkhite-Canada syndrome (CCS) was quickly established and the patient was treated with corticosteroids (prednisolone 50 mg orally q. d.). This led to a prompt response, especially his diarrhea improved markedly within a short period of time. Since his radial fracture did not develop a proper callus, tapering of steroids had been tried, however, relapsing severe diarrhea required the prompt step-up in dosage.

Eleven months after the initial diagnosis the patient was transferred to our hospital due to ongoing malnourishment (Table 1). Laboratory workup showed severe iron deficiency with microcytic anemia, hypoproteinemia, and hypalbuminemia. The patient’s blood pressure was low at 110/70 mmHg.

Barium contrast enema showed multiple polypoid lesions throughout the colon as well as smaller lesions in the upper GI tract. Endoscopies of the stomach, upper and lower GI tract confirmed these findings, showing an extensive polyposis of the stomach, the small intestine as well as the colon. The size and numbers of the broad based polyps decreased aborally and their endoscopic appearance resembled the typical aspect of polyps upon polyps (Fig. 2). The gastric tissue biopsies showed cystic enlargement of crypts with edema and inflammatory stroma infiltrates, mainly consisting of plasma cells and lymphocytes. The analysis of duodenal and jejunal polyps resulted in similar findings with cystic enlargement of mucine containing glands, a stromal

---

**Fig. 1** Ectodermal alterations before (A/C) and after (B/D) combined therapy with corticosteroids and mesalazine. a Finger nail dystrophy, b regular nails, c alopecia, d regular hair growth
edema and a dense inflammatory infiltrate (Fig. 3). IgG4-immunohistochemistry showed a very faintly positive signal.

After ruling out malabsorption, bacterial overgrowth, lactose intolerance or celiac sprue, the patient was put on a diet rich in protein as well as zinc supplements, and mesalazine (1000 mg orally t.i.d.) was administered together with prednisolone at a dose of 10.0 mg/d.

A combination of prednisolone and mesalazine 1500 mg/d had been proven to be effective with regard to symptoms and regression of colonic polyps in an earlier published case report [19]. However, we decided to use a higher mesalazine dose well within the recommended range (2.0–4.8 g/d in three divided doses) for the oral treatment of ulcerative colitis at that time [20].

This therapy led to a weight gain of 9 kg during the following 6 months and a normalization of serum albumin levels, while serum zinc levels remained low. Hence, the prednisolone dose was reduced to 7.5 mg/d, the mesalazine dose remained the same. During the following year, steroids were further tapered and the patient’s nails regrew (Fig. 1b and d) and a repeated endoscopy of the stomach and proximal small intestine showed a reduced number of polyps. At this point it was decided to stop the steroids and three years after the initiation of mesalazine therapy, all polyps had disappeared. The dosage of mesalazine was kept at 1000 mg t.i.d. for another year, followed by 500 mg t.i.d. for one year with a stepwise reduction (500 mg each year) thereafter. Finally, mesalazine was stopped and more than 14 years after the initial diagnosis the patient is still in complete remission without any treatment.

**Discussion and conclusions**

Optimal medical therapy in CCS remains unclear and several strategies have been described. Corticosteroids improve exudative enteropathy in 90.0–93.0% of all patients [4]. Targeted diets and supplements are used to treat malnutrition and ectodermal alterations [1, 17, 19, 21, 22]. Antibiotics are used to combat bacterial overgrowth or to treat co-infections and septicemia [17]. Corticosteroids are recommended as the mainstay of medical treatment

| Parameter          | On admission | At the end of therapy | Normal range               |
|--------------------|--------------|-----------------------|----------------------------|
| Hemoglobin (g/dl)  | 9.2          | 13.3                  | 13.5–18                    |
| MCV (fl)           | 72           | 86                    | 80–96                      |
| Leucocytes (x1E9/l)| 7.48         | 6.90                  | 4.4–11.3                   |
| Thrombocytes (x1E9/l)| 369       | 171                   | 150–400                    |
| Erythrocytes (x1E12/l)| 4.3      | 4.5                   | 4.4–5.9                    |
| Potassium (mmol/l) | 3.0          | 4.3                   | 3.6–4.8                    |
| Chloride (mmol/l)  | 107          | 103                   | 94–110                     |
| Magnesium (mmol/l) | 0.67         | 0.73                  | 0.7–1.1                    |
| Calcium (mmol/l)   | 2.29         | 2.45                  | 2.20–2.65                  |
| Total protein (g/l)| 60           | 75                    | 66–83                      |
| Albumin (g/l)      | 34           | 45                    | 35–52                      |
| ALT (U/l)          | 16           | 12                    | 10–50                      |
| AST (U/l)          | 13           | 17                    | 10–50                      |
| LDH (U/l)          | 178          | 165                   | 135–225                    |
| Iron (μmol/l)      | 2.6          | 2.04                  | 9.0–30.0                   |
| Ferritin (μg/l)    | 4            | 166                   | 30–400                     |
| Transferrin (g/l)  | 2.83         | 2.90                  | 2.00–4.00                  |
| Transferrin saturation (%) | 4  | 30                   | 16–45                      |
| Amylase (U/L)      | 29           | 30                    | 13–53                      |
| Lipase (U/l)       | 32           | 35                    | 13–60                      |
| CRP (mg/l)         | < 3          | < 3                   | < 8                        |
| ESR (mm/h)         | 29           | 16                    | < 14                       |
| TSH (mU/l)         | 0.84         | 2.80                  | 0.27–4.20                  |
| Zinc (μmol/l)      | 8.7          | 11.7                  | 10.6–17.9                  |
| Vitamin B12 (ng/l)| 214          | 282                   | 181–701                    |
and have been used in various combinations, e.g. antiplasmin therapy, H2-receptor antagonists, proton pump inhibitors, or cromolyn sodium. Takakura et al. [19] were the first to describe a direct response to a combination therapy of prednisolone (25 mg/d) together with mesalazine (1500 g/d) leading to a reduction in polyposis, abdominal pain and diarrhea within 6 months. This regimen also had positive effects on upper GI polyposis [23].

Mesalazine is known for its role in the treatment of chronic inflammatory bowel disease, it reduces pro-inflammatory prostaglandins and leukotrienes and inhibits cytokines. Independent from its anti-inflammatory features it appears to have an antiproliferative effect on colorectal adenomas [24].

The exact mechanism of action, especially in the upper GI tract, including in our case, remains unclear. Our patient received Pentasa® (Ferring Pharmaceuticals, Copenhagen, Denmark) consisting of ethylcellulose-covered microgranula which continuously release their content from duodenum to ileum in a pH- and time-dependent way allowing systemic absorption (25.0 to 30.0%) during the passage of the small intestine [25–27].

In our case, the patient showed a good initial response to corticosteroid therapy, paired with nutritional supplements. However, we were faced with the problem of continued malnutrition and a non-healing distal radius fracture which required tapering steroids in the long run. This resulted in our decision to initiate mesalazine therapy and we opted for a dose within the recommended range (2.0–4.8 g/d in three divided doses) for the treatment of ulcerative colitis at that time [20].

Recently another case of CCS with longstanding remission has been published, however, in that case anti-inflammatory and immunosuppressive medications in addition to nutritional support resulted in sustained disappearance of clinical manifestations as well as the persistence of physical and psychological well-being over more than eight years [28]. Our case also argues against the poor prognosis previously ascribed to patients with this syndrome. The successful combination of mesalazine with prednisolone in CCS as initially published by Takakura et al. [19] was confirmed and additionally a longstanding remission following a four year mesalazine monotherapy was shown.

Fig. 3 Histology: gastric mucosa with cystic enlargement of crypts, edema and inflammatory stroma infiltrates, mainly consisting of plasma cells and lymphocytes (a). Duodenal polyp with edema und inflammatory stroma infiltration (b). Jejunal polyp with cystic elongation of glands, edema and inflammatory stroma infiltration (c).

Abbreviation
CCS: Cronkhite-Canada syndrome

Acknowledgements
Not Applicable.

Funding
No funding was obtained for this study.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.

Authors’ contributions
SS and FK drafted the manuscript. HMS conducted care and outpatient treatment of the patient and initiated this case report. TK diagnosed the CCS. JM, TK, UT and HMS performed the endoscopic examinations. UD performed the histopathological examinations. HMS, DN and UT critically revised the manuscript for important intellectual content and gave final approval of the version to be published. All authors read and approved the final manuscript.
Cronkhite-Canada syndrome: epidemiological study of 110 cases

3. Sweetser S, Ahlquist DA, Osborn NK, Sanderson SO, Smyrk TC, Chari ST,
1. Cronkhite LW Jr, Canada WJ. Generalized gastrointestinal polyposis; an
4. Goto A. Cronkhite-Canada syndrome: epidemiological study of 110 cases

References
1. Cronkhite LW Jr, Canada WJ. Generalized gastrointestinal polyposis; an unusual syndrome of polyposis, pigmentation, alopecia and onychotrophia. N Engl J Med. 1955;252(24):1011–5.
2. Choi YJ, Lee DH, Song EJ, Kim JW, Chae HS, Vitiglo: an unusual finding in Cronkhite-Canada syndrome. J Dermatol. 2013;40(10):848–9.
3. Sweetser S, Ahkquist DA, Osborn NK, Sanderson SO, Smyrk TC, Chari ST, Boardman LA. Clinico-pathologic features and treatment outcomes in Cronkhite-Canada syndrome: support for autoimmunity. Dig Dis Sci. 2012;57(2):496–502.
4. Goto A. Cronkhite-Canada syndrome: epidemiological study of 110 cases reported in Japan. Nippon Geka Gakkan. 1995;56(1):3–14.
5. Daniel ES, Ludwig SL, Lewin KJ, Ruprecht RM, Rajach M, Schwabe AD. The Cronkhite-Canada syndrome. An analysis of clinical and pathologic features and therapy in 55 patients. Medicine (Baltimore). 1982;61(5):293–309.
6. Hsu YQ, Loke SL. Cronkhite Canada syndrome. Gastrointest Endosc. 2003;57(7):917.
7. Slavik T, Montgomery EA. Cronkhite-Canada syndrome six decades on: the many faces of an enigmatic disease. J Clin Pathol. 2014;67(10):891–7.
8. Peart AG Jr, Sivak MV Jr, Rankin GB, Kish LS, Steck WD. Spontaneous improvement of Cronkhite-Canada syndrome in a postpartum female. Dig Dis Sci. 1984;29(5):470–4.
9. Malhotra R, Sheffield A. Cronkhite-Canada syndrome associated with colon carcinoma and adenomatous changes in I/C polyps. Am J Gastroenterol. 1988;83(7):772–6.
10. Nagata K, Sato Y, Endo S, Kudo SE, Kusihashi T, Umesato K. CT endoscopy for the follow-up of Cronkhite-Canada syndrome. Int J Color Dis. 2007;22(9):1131–2.
11. Nakatubo N, Wakasa R, Kyosaki K, Matsui K, Konishi F. Cronkhite-Canada syndrome associated with carcinoma of the sigmoid colon: report of a case. Surg Today. 1997;27(4):345–8.
12. Rappaport LB, Sperling HV, Stavrides A. Colon cancer in the Cronkhite-Canada syndrome. J Clin Gastroenterol. 1986;8(2):199–202.
13. Watanabe T, Kudo M, Shirane H, Kashida H, Tomita S, Orino A, Todo A, Chiba T. Cronkhite-Canada syndrome associated with triple gastric cancers: a case report. Gastrointest Endosc. 1999;50(5):688–91.
14. Zong Y, Zhao H, Yu L, Ji M, Wu Y, Zhang S. Case report-malignant transformation in Cronkhite-Canada syndrome polyp. Medicine (Baltimore). 2017;96(6):e6051.
15. Yashiro M, Kobayashi H, Kubo N, Nishiguchi Y, Wakasa K, Hirakawa K. Cronkhite-Canada syndrome containing colon cancer and serrated adenoma lesions. Digestion. 2004;69(1):57–62.
16. Sweetser S, Alexander GL, Boardman LA. A case of Cronkhite-Canada syndrome presenting with adenomatous and inflammatory colon polyps. Nat Rev Gastroenterol Hepatol. 7(8):460–4.
17. Ward EM, Wolfson HC. Pharmacological management of Cronkhite-Canada syndrome. Expert Opin Pharmacother. 2003;4(3):385–9.
18. Błonski WC, Furth EE, Kinosian BP, Compher C, Metz DC. A case of Cronkhite-Canada syndrome with taste disturbance as a leading complaint. Dig. 2005;71(4):201–5.
19. Takakura MAH, Tsuchihashi N, Miyazaki E, Yoshikawa Y, Yoshida K, Oya F, Sawada T. A case of cronkhite-Canada syndrome markedly improved with mesalazine therapy. Dig Endosc. 2004;16:74–8.
20. Kombliuth A, Sachar DB. Practice parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99(7):1371–85.
21. Hanzawa M, Yoshikawa N, Tezuka T, Konishi K, Kaneko K, Akita Y, Mitamura K, Tsunoda A, Takada M, Kusano M. Surgical treatment of Cronkhite-Canada syndrome associated with protein-losing enteropathy: report of a case. Dis Colon Rectum. 1998;41(7):932–4.
22. Ward E, Wolfson HC, Ng C. Medical management of Cronkhite-Canada syndrome. South Med J. 2002;95(2):272–4.
23. Zimmer V, Gunnahge F, Jungeling B, Kraemer J, Bohle RM, Lammert F. A stomach carpeted red. Dig Liver Dis. 2011;43(4):324–5.
24. Munding J, Ziebarth W, Pox CP, Ladigat S, Reiser M, Huppe D, Brand L, Schmiegel W, Tannapfel A, Reinacher-Schick AC. The influence of S-aminosalicylic acid on the progression of colorectal adenomas via the beta-catenin signaling pathway. Carcinogenesis. 2012;33(3):637–43.
25. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;12. CD008870.
26. Rasmussen SN, Bondeisen S, Hvidberg EF, Hansen SH, Binder V, Hallak S, Flachs H. S-Aminosalicylic acid in a slow-release preparation: bioavailability, plasma level and excretion in humans. Gastroenterology. 1982;83(5):1062–70.
27. Yu A, Baker JR, Fioritto AF, Wang Y, Luo R, Li S, Wen B, Bly M, Tsune Y, Koenigsknecht MJ, et al. Measurement of in vivo gastrointestinal release and dissolution of three locally acting Mesalamine formulations in regions of the human gastrointestinal tract. Mol Pharm. 2017;14(2):345–58.
28. Dore MP, Satta R, Munno A, Pes GM. Long-lasting remission in a case of Cronkhite-Canada syndrome. BMJ Case Rep. 2018;bcr-2017-223527.